MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer

Li Xue; Xiujuan Han; Rongrong Liu; Ziming Wang; Hecheng Li; Qi Chen; Peng Zhang; Zhenlong Wang; Tie Chong

doi:10.18632/oncotarget.3923

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer

Li Xue, Xiujuan Han, Rongrong Liu, Ziming Wang, Hecheng Li, Qi Chen, Peng Zhang, Zhenlong Wang and Tie Chong _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:31825-31831. https://doi.org/10.18632/oncotarget.3923

Metrics: PDF 1664 views | HTML 2251 views | ?

Abstract

Li Xue1,*, Xiujuan Han2,*, Rongrong Liu3, Ziming Wang1, Hecheng Li1, Qi Chen1, Peng Zhang1, Zhenlong Wang1 and Tie Chong1

1 Department of Urology, The Second Affiliated Hospital, Xi’an Jiaotong University, Xian, China

2 The Helmholtz Sino-German Research Laboratory for Cancer, Department of Pathology, Tangdu Hospital, The Fourth Military Medical University, Xian, China

3 Department of Pathology, School of Basic Medicine, Fourth Military Medical University, Xian, Shaanxi, China

* These authors have contributed equally to this work

Correspondence to:

Tie Chong, email:

Keywords: MDM2 gene; p53 gene; prostate cancer; risk; survival

Received: March 11, 2015 Accepted: April 08, 2015 Published: May 18, 2015

Abstract

The p53 gene and MDM2 gene play critical roles in cell cycle arrest and apoptosis together. Here, we evaluated the associations of prostate cancer risk and survival with the joint effects of mdm2 and p53 polymorphisms. Totally 1,193 cases and 1,310 age frequency-matched controls were included in the study. Prostate cancer patients were followed to determine the intervals of overall survival and disease-free survival. The Pro72Arg Pro allele (homozygous and heterozygous) were significantly associated with prostate cancer risk with an odds ratio (OR) of 0.77 [95% confidence interval(CI), 0.64-0.93]. SNP309 T alleles were associated with a significantly decreased prostate cancer risk among Pro72Arg Pro alleles carriers (OR=0.79, 95% CI, 0.64-0.98). In addition, comparedwith the Pro72Arg Pro alleles and SNP309 G homozygous, patients carrying both SNP309 T alleles and Pro72Arg Arg homozygous had more favorable disease-free survival (hazard ratio [HR] = 0.59, 95% CI, 0.38-0.93). Our results indicated that SNP309 and Pro72Arg polymorphisms may jointly contributeto the etiology and prognosis of prostate cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3923

Publication Alerts

Research Papers:

MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer

Abstract